retatrutide ada 2025 results Back in 2023 we saw truly unprecedented data for a new drug called ' Retatrutide', which binds to — and activates — 3 receptors: the GLP1 receptor (like Semaglutide), the GIP receptor (like Retatrutide Phase 3: 60% Achieved

These drugs have anti-fibrotic characteristics by obstructing transforming growth factor- (TGF-) signaling and diminishing collagen accumulation in models of diabetic nephropathy (Tian et al

At minimum: IGF-1 every 4 weeks, fasting glucose and insulin every 2 weeks initially (monthly once stable), HbA1c every 6 weeks, liver enzymes monthly, and comprehensive metabolic panel quarterly

Nevertheless, it can take a few weeks for the drug to leave the body entirely

it turns fragile the moment they stall

By supporting healthy serotonin levels, this naturally occurring amino acid helps regulate mood and reduce emotional eating patterns

Compounded Semaglutide